List view / Grid view
In the past two decades, several alternative, non-radiometric assay formats have been developed for the high-throughput screening (HTS) of target classes such as protein kinases, which were previously screened using radiometric assays. Radiometric screening (and the expertise to perform such HTS) has thus declined in recent years...
Neglected tropical diseases pose a significant threat to public health and affect nearly one billion people in tropical and sub-tropical regions throughout the world. There is a pressing need to identify new therapeutics for NTDs and many developed nations are participating in drug discovery efforts...
29 January 2016 | By SMi Group
SMi group reports: Doug Johnson, Research Fellow at Pfizer will be giving a keynote address on Day 1 at the SMi’s 15th annual Advances and Progress in Drug Design conference...
Progress in the understanding of disease mechanisms provides new opportunities to discover molecules that modulate disease. To capitalise on these opportunities, successful lead discovery strategies need to build on insights into how a cellular phenotype or a target contributes to disease biology. Recent advances in induced pluripotent stem cells (iPSCs),…
20 November 2015 | By Victoria White
The compound exchange represents a novel, open innovation model of collaboration between the two companies.
Undoubtedly, you will have noticed the increase in the number of publications utilising flow cytometry, heard it mentioned more in meetings and probably even been targeted by several companies trying to sell you their latest cytometer. The rapidly advancing technology behind the cytometer and an increase in applications that use…
19 August 2015 | By Victoria White
Scientists have developed a potentially better and more accurate high-throughput screening technique and have used it to identify 24 drug candidates...
High throughput screening (HTS) continues to be employed in drug discovery as the primary source of identifying chemical starting points for drug discovery and tool compounds for chemical biology, respectively. Although small molecule drug discovery efforts have focused largely upon enzyme, receptor and ion-channel targets, there has been an increase…
10 June 2015 | By Kenji Schorpp, Kamyar Hadian, Sheraz Gul, Horst Flotow
In this Screening In-Depth Focus, high throughput screening is the topic focused on by Kenji Schorpp and Kamyar Hadian, Institute of Molecular Toxicology and Pharmacology, and Sheraz Gul, Fraunhofer Institute for Molecular Biology and Applied Ecology. They discuss the importance of the technique in drug discovery today as well as…
From the beginning of time in the drug discovery world, the integration of disciplines has driven the identification of new lead molecules. Chemists, pharmacologists and biologists work together to understand a disease state and how to perturb that state back towards a normal healthy condition. However, in the early days…
2 March 2015 | By MRC Technology
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease...
Chemokines orchestrate leukocyte trafficking in the immune system, but unregulated or inappropriate chemokine activity plays a key role in many inflammatory, allergic and autoimmune diseases as well as metastatic tumour progression. The chemokine network is comprised of ~50 distinct ligands that specifically bind and activate a family of 20 G…
19 March 2014 | By Daiichi Sankyo
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
29 October 2013 | By Kenji Schorpp, Assay Development and Screening Scientist, Helmholtz Center.
Kenji Schorpp, Assay Development and Screening Scientist, talks to Drug Target Review about his work at the Helmholtz Center...
